Who are Lapaquistat acetate and simvastatin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lapaquistat-acetate-and-simvastatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Lapaquistat acetate and simvastatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Lapaquistat acetate and simvastatin (Lapaquistat acetate and simvastatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACAT inhibitor + HMG-CoA reductase inhibitor (statin combination). Area: Cardiovascular.

phase 3 ACAT inhibitor + HMG-CoA reductase inhibitor (statin combination) ACAT (acyl-CoA:cholesterol acyltransferase) and HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Lapaquistat acetate and simvastatin (Lapaquistat acetate and simvastatin) — Takeda. Lapaquistat acetate inhibits ACAT (acyl-CoA:cholesterol acyltransferase) to reduce cholesterol absorption, while simvastatin inhibits HMG-CoA reductase to decrease cholesterol synthesis, providing dual lipid-lowering effects.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lapaquistat acetate and simvastatin TARGET	Lapaquistat acetate and simvastatin	Takeda	phase 3	ACAT inhibitor + HMG-CoA reductase inhibitor (statin combination)	ACAT (acyl-CoA:cholesterol acyltransferase) and HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACAT inhibitor + HMG-CoA reductase inhibitor (statin combination) class)

Takeda · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lapaquistat acetate and simvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/lapaquistat-acetate-and-simvastatin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab